Zuno General Insurance Unveils “Zuno HealthPlus Policy”: An Affordable & customisable Health Insurance plan

Highlights

The policy offers cover from sum insured 5 lakhs to INR 5 crores, no Room Rent Capping 

Unlimited Restore for unrelated ailments, 2X benefit from day 1 under Recharge benefit for related ailments. 

No claim bonus – Sum Insured doubles in 2 claim-free years. 

No sublimits or disease wise capping, no age-based co-payment. 

Zuno General Insurance, a new-age digital insurer, introduces its latest health insurance policy - Zuno HealthPlus Policy. This innovative health insurance plan is designed to provide tailored coverage and benefits for individuals and families at an affordable premium.  

This inflation-adjusted product allows coverage for up to 9 family members under a single policy, streamlining the process of managing multiple policies.  

Zuno HealthPlus Policy caters to diverse needs, allowing individuals and families to choose from 20 different relationships for coverage. Product where a bachelor can insure themselves with a basic health insurance and opt for adventure sports optional cover. Young couples can go for plans with maternity benefits and newborn covers. Looking at rising infertility, intending couples may also opt for infertility and surrogacy covers. A family with children can choose to go with Outpatient and worldwide covers. With no maximum entry age barrier, this policy offers cover to senior citizen. 

In addition to these features, to make it even more accessible, policyholders can enjoy up to 20% zone-based discount based on their geographical location. Additionally, the policy offers long term discount of up to 10% and incentivise an existing customer with 5% discount on purchasing this policy. Not only this, but you also get a discount of 15% if you purchase directly from our website. 

Announcing the launch of the new policy, Shanai Ghosh, MD & CEO of Zuno General Insurance said, "Zuno HealthPlus Policy reflects our commitment to innovation and customer-centric solutions. We believe in making insurance simple, easy to understand and accessible to all. Zuno HealthPlus Policy is a significant step in that direction. With high sums insured, no room rent capping, no sublimit or disease wise capping including modern treatments and comprehensive coverage, it’s not just an insurance —it's peace of mind" 

The new policy will primarily be accessible through its network of channel partners. Zuno HealthPlus Policy also gives leverage to its customer when it comes to medical screening. There will not be any medical test for coverage up to 20 lakhs, age of 55 years without extreme health conditions. 

Zuno HealthPlus Policy ensures hassle-free healthcare with an extensive network of over 10,000 cashless hospitals. In times of emergency, the vast network eliminates the concern of finding a suitable facility. In case of admission to a non-network hospital, Zuno makes efforts to onboard it for cashless facilities. For reimbursement claims, Zuno offers “Cash in Advance” facility, where Zuno pays an advance payment to the customer providing immediate support in emergencies. The 24 x 7 Claims Concierge provides expert guidance throughout the claims process ensuring prompt and seamless support to the policyholders making the customer experience stress-free.  

Zuno General Insurances is confident that Zuno HealthPlus Policy will set a new standard for health insurance products, combining innovative features with a commitment to affordability and a customer-centric approach. For more information on Zuno HealthPlus Policy and other insurance products, please visit our website https://www.hizuno.com/  

About Zuno General Insurance: 

Zuno General Insurance, formerly known as Edelweiss General Insurance, is a new-age digital insurer with an aspiration to reimagine Insurance to make it easy, friendly, and transparent. Amidst all the jargon and seriousness, Zuno is the friendly voice speaking in a language you understand, and listening to what you have to say, stepping in at the right time, so that you don’t have to worry when things don’t go as planned. Zuno is the friend you can always turn to for help, with the confidence that we will have your back at all times. 

At Zuno GI, the focus is on building trust through digital solutions that are intuitive and responsive, using consumer insights and data analytics to drive innovation and experience. Our consumer insight driven strategy focused on customers experience, innovative solutions and an intuitive digital platform differentiates us in a competitive market. 

Zuno GI started operations in 2018. We have over 3 million customers and a growing omnichannel distribution on digital rails. The company has presence across key digital marketing places and partnerships with Maruti, Tata Motors, Mahindra, Skoda, Volkswagen, Jeep, OLA, PolicyBazaar, Turtlemint, Dunzo, PhonePe, Insurance Dekho, Fedbank Financial Services, Dvara KGFS, Repco Home Finance, ART Housing Finance, Renewbuy, Bajaj Capital, Anandrathi Global Finance, Avanse Financial Services, Zopper, Spinny, etc. 

SecurEyes Cyber Security Certification Program Welcomes Aspiring Professionals For The February 2024 Batch

SecurEyes, a leading cyber security firm based in engaluru, is excited to announce the commencement of its highly sought-after Cyber Security Certification Program for the February 2024 batch.

Seemanta Patnaik, CTO and Co-founder of SecurEyes, emphasizes the crucial role that cyber security professionals play in fostering an environment of progress and safety. "Progress cannot happen in an insecure environment. Cybersecurity professionals are a key link to the emotional and physical safety of individuals, businesses, and governments. It's a big job, with a lot of built-in job satisfaction," said Patnaik.

Mr. Karmendra Kohli, CEO and Co-founder of SecurEyes, emphasizes the importance of staying one step ahead of cybercriminals. "Your cybersecurity journey will not only depend on your specific skillset but also on your unique interests to learn. Our program is designed to equip you with the latest knowledge and practical skills to excel in this ever-evolving field," says Kohli.

In an era where cybercrimes loom large and the demand for skilled professionals is at an all-time high, SecurEyes stands resolute, offering an ideal platform for individuals aspiring to become an expert in the dynamic field of cyber security.

The 10th batch of this comprehensive three-month online course is set to kick off in February, 2024, marking another milestone in the company's commitment to cultivating a cadre of adept cyber defenders.

According to a recent study conducted by the International Information System Security Certification Consortium, there is a staggering shortage of nearly 4 million cyber security professionals worldwide. SecurEyes recognizes this gap and aims to bridge it by empowering individuals with the knowledge and skills needed to combat the ever-evolving cyber threats.

The global digital economy, valued between USD 25 trillion to USD 30 trillion, indicates  to the transformative power of technology. Unfortunately, with the digital revolution comes the dark side - cybercrime, a permanent feature in our interconnected world. SecurEyes acknowledges the vital role of cyber security professionals in maintaining the integrity of the digital realm.

To ensure a holistic learning experience, the February 2024 batch will benefit from live sessions conducted by cybersecurity experts actively engaged in real-world projects from around the globe. Students will have 24X7 access to online labs and comprehensive study material covering key concepts such as Information Security, Network Security, Infrastructure Security, Application Security, Governance, Risk & Compliance, Security Operations, and Incident Management.

As the digital landscape continues to evolve, so does the need for vigilant guardians against the rising tide of cyber threats. Every industry recognizes the critical need for skilled cybersecurity professionals to safeguard networks, data, and online transactions. SecurEyes Cyber Security Certification Program aims to nurturing the next generation of cyber defenders.

For further details please click here: https://secureyes.net/cscp/index.html

ABOUT SECUREYES

SecurEyes is a leading global cyber security specialised consulting services and suptech product development firm incorporated in 2006 with offices in India, USA, UAE and KSA. It is empanelled with CERT-IN and specialises in developing state-of-the-art innovative technology products to provide complex business solutions.

SecurEyes products are built using the latest technologies including Angular, NodeJS, NET and rely on use of a relevant mix of machine learning, artificial intelligence securely and efficiently.

SecurEyes clients include regulatory bodies for key industry sectors, large government organisations, banking majors, financial services institutions, insurance companies, international airlines, large trading houses and public sector companies in over a dozen countries.

The firm recently received UK’s Central Banking Award in London for its flagship product- RegTech.

Samsung Opens Pre-Reserve For The Next Galaxy Smartphone In India

Samsung, India’s largest consumer electronics brand, announced the pre-reserve of its next flagship Galaxy smartphone, which will be unveiled later this month. Pre-reserved customers will be eligible for early access and special offers on purchasing the new Galaxy devices.

Customers can pre-reserve the flagship Galaxy devices by paying a token amount of INR 2000 on Samsung.com, Samsung Exclusive stores, Amazon.in and leading retail outlets across India. Consumers who pre-reserve will get benefit worth INR 5000.  

Since the introduction of the first Galaxy flagship, Samsung has been continuously enhancing and innovating the flagship experience for the consumers. With the next generation of the flagship, offering enhanced devices based on years of rigorous R&D and investment, Samsung aims to further drive the latest era of Galaxy innovation and consolidate its position as the industry leader.

Samsung will unveil its next generation of flagship devices at Galaxy Unpacked on January 17 in San Jose, California.

Glenmark Is The First To Launch Biosimilar Of Popular Anti-Diabetic Drug, Liraglutide, In India

-          The anti-diabetic biosimilar has been launched under the brand name Lirafit™, and is indicated for improving glycemic control in adult patients with type 2 diabetes mellitus.1

-          Clinical trials on Liraglutide have demonstrated several benefits, including effectively lowering glycemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus.2,3,4,5

-          Liraglutide belongs to the class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) that are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co-morbidities, like established atherosclerotic cardiovascular disease and obesity.6,7,8,9

-          Lirafit™ will sharply lower the daily cost of therapy by around 70% to around INR 100; making the drug more accessible to a larger number of patients with type 2 diabetes mellitus in the country.

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has launched a biosimilar of the popular10,11 anti-diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit™ following the approval from the Drug Controller General of India (DCGI). Priced at around INR 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription.

Liraglutide belongs to the class of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, which increase glucose-dependent insulin secretion and decrease in appropriate glucagon secretion.12,13  It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union.14

“Glenmark is proud to introduce Lirafit™, a novel and affordable biosimilar of the drug liraglutide, for the first time in India. Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity.1-5 Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus.4,5,7,14,15 With this launch, we have now ventured into the injectable anti-diabetic market taking another significant stride in the diabetes therapy space,” remarked Alok Malik, President and Business Head ? India Formulations, Glenmark Pharmaceuticals Ltd.

Liraglutide and its role in the treatment of type 2 diabetes

Liraglutide has a proven efficacy in improving glycemic control in patients with type 2 diabetes mellitus. Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24-week period have demonstrated Lirafit™ to be effective, safe and well-tolerated. The trials also revealed non-inferior efficacy and a safety profile with that of the reference liraglutide.16 Additional benefits of liraglutide include effectively lowering glycemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus2-5,13,14.           

GLP-1 RA class of drugs and their mechanism of action

GLP-1 RA (Glucagon-like peptide-1 receptor agonists) are a group of drugs used in the treatment of type 2 diabetes.13 GLP-1 RAs are very effective in lowering blood sugar levels. Several trials have demonstrated that GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio-renal outcomes beyond their blood glucose-lowering effects in type 2 diabetes mellitus patients.17,18 Their mechanism of action involves the release of insulin, in the presence of elevated glucose concentrations, thus decreasing glucagon secretion.12,13 GLP-1 RAs are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co-morbidities, like established atherosclerotic cardiovascular disease and obesity.6,7,8,9. The American Diabetes Association (ADA) also recommends GLP1RAs therapy for weight loss & lesser risk of hypoglycemia in type 2 diabetes mellitus patients.6,7 Drugs belonging to this class include liraglutide, semaglutide, and dulaglutide, among others.

Glenmark’s expertise in diabetes management

Glenmark has a strong legacy of bringing in new, effective, and affordable treatment options for diabetic patients, especially for those suffering from uncontrolled Type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus® and Ziten®), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus® and Ziten-M®). Glenmark later introduced Remogliflozin (Remo® and Remozen™), a novel SGLT-2 inhibitor in 2019; and subsequently, its combinations (Remo-V®, Remozen™-V, Remo MV®, and Remozen™ MV). Glenmark followed that up with the launch of Sitagliptin (Sitazit®) and its FDCs in 2022. Then came Lobeglitazone (LOBG®) and additional FDCs of Teneligliptin, including its combinations with Pioglitazone (Zita Pio™), Pioglitazone + Metformin (Zita®-PioMet), Dapagliflozin (Zita-D™), and Dapagliflozin + Metformin (Zita® DM). Liraglutide (Lirafit®), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) is the latest affordable offering from Glenmark, marking its entry into the injectable anti-diabetic market.

Prevalence of diabetes in India

As per the ICMR-INDIAB study conducted between October 2008 and December 2020, the overall weighted prevalence of diabetes was 11.4%19. According to IQVIA™ sales data for the 12?month period ending August 2023 (MAT August 2023), the market for GLP-1 RA in India is estimated to be INR 259 crores, with an annual growth of 108% against the corresponding period last year (MAT August 2022).

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK) is a research?led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. The company has also been Great Place To Work® Certified™ in India for FY 2023. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

References:

*        HbA1c is the average blood glucose (sugar) levels for the last two to three months

1.        Liraglutide (Lirafit) prescribing information

2.        Nauck, M.; Frid, A.; Hermansen, K.; et al. For the LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32, 84–90.

3.        Russell-Jones, D.; Vaag, A.A.; Schmitz, O.; et al. On behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009, 52, 2046–2055.

4.        Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 311–322.

5.        Marso, S.P.; Baeres, F.M.; Bain, S.C.; et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients with Diabetes With or Without Heart Failure. J. Am. Coll. Cardiol. 2020, 75, 1128–1141.

6.        Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023 May;29(5):305-340

7.        Byrne RA, Rossello X, Coughlan JJ, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826.

8.        American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S17

9.        Kumar V, Agarwal S, Saboo B, Makkar B. RSSDI Guidelines for the management of patients with diabetes mellitus. Int J Diabetes Dev Ctries. 2022 Dec 15;42(Suppl 1):1-30

10.     National Institutes of Health. Available from: https://www.nih.gov/news-events/news-releases/two-popular-diabetes-drugs-outperformed-others-large-clinical-trial. Accessed on 20th Dec 2023

11.     Poku C, Tahsin B, Fogelfeld L. Weight loss: lifestyle interventions and pharmacotherapy. Obesity Hypoventilation Syndrome. Academic Press; 2020: 219-234.

12.     Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021 Mar 9; 12:2042018821997320.

13.   Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2023 Jan 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Accessed on 27th Nov 2023, Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/

14.   Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753-67

15.     Mann JFE, Ørsted DD, Brown-Frandsen K, et al; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848

16.     Krishnan K, Raman S, Anand Moses CR, et al. Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2023 Dec 5; 207:111034

17.     Tilinca MC, Tiuca RA, Burlacu A, et al. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review. Medicina (Kaunas). 2021 Jun 29;57(7):669

18.     Yu JH, Park SY, Lee DY, Kim NH, Seo JA. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin Pract. 2022 Mar;41(2):136-149.

19.    ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489.

Information Technology: ER&D: Well Poised For Growth Acceleration

We expect pure play engineering research & development (ER&D) companies to benefit from the likely acceleration in ER&D spend, growing digitization, and rising share of sourcing. ER&D spend has a high correlation with industry cycles and is thus prone to macro factors in the short term. But many industries like Auto are undergoing significant technology transition/disruptions that are driving higher spends on ER&D—this would negate any near-term weakness in other segments due to macro factors. Developed economies are expected to face shortage of skilled talent which will drive sustainable opportunities and sourcing from the engineering talent-rich Indian market. Nifty IT index inched up ~8%/11% in the last 1M/3M, on hopes of higher rate cuts in USA in CY24. ER&D stocks also saw a similar/better upmove which may cap any near-term upside; however, improving medium-term growth outlook would support higher valuations, in our view. We initiate coverage on Cyient with a BUY recommendation and TP of Rs2,700/share, and on LTTS with a REDUCE and TP of Rs5,050/share.

ER&D Services market well poised for growth

The ER&D Services market is set to see acceleration in growth momentum, on the back of: i) anticipated spurt in global ER&D spending, which is expected to register 8-9% CAGR over 2023-30 compared with 7-8% CAGR over 2020-23; ii) rising share of fast-growing, digital-engineering spends that are expected to clock 12-13% CAGR over 2023-30, with share inching up to ~65% of spend in 2030; iii) higher ER&D sourcing, which is likely to log ~16% CAGR over 2023-30, driven by sourcing decisions of global corporates focusing on resilience and agility post the aftermath of the pandemic, market expansion, evolving manufacturing footprint, cost dynamics, and access to new-age, digital-ready talent.

Indian ERD Service providers likely to benefit from growing sourcing trends

ER&D sourcing (captives or third-party providers) is likely to see ~16% CAGR over 2023-30, almost 2x of the global ER&D spend growth. As per the Bain report on ER&D, the sector sees far less outsourcing than the IT Services sector, which underwent a similar transformation in the 2000s. As the innovation pace hastens, enterprises are likely to see rise in sourcing, for managing skills requirement and cost & time-to-market constraints. Share of ER&D sourcing is expected to rise to 24% of the global ER&D spend by 2030 from 15% in 2023. India’s share of global ER&D sourcing is estimated to grow to 22% in 2030 from 17% in 2023, assisted by a skilled talent pool, favorable demographics, installed ER&D capacity, thriving start-up ecosystem, and talent competitiveness (upskilling/reskilling). Automotive, Software, and Healthcare & Medical Devices segments are expected to drive ~50% of the incremental ER&D spend by 2030, and players with higher exposure to such verticals are likely to benefit from this trend.

We initiate coverage on ER&D players Cyient (BUY) and LTTS (REDUCE)

ER&D players would benefit from industry growth tailwinds in the medium term, but valuations already factor this in to some extent, in our view. ER&D services stocks moved up in the last 1M/3M, on hopes of higher rate cuts in USA in CY24 which may cap any upside in the near term. However, improving medium-term growth outlook would support higher valuations. We initiate coverage on Cyient with BUY and TP of Rs2,700/sh, given relatively reasonable valuations, anticipated double-digit revenue growth trajectory, progress on margin trajectory, and steps to improve performance consistency. LTTS benefits from its strong engineering parentage and well-diversified portfolio, but given its rich valuations, we initiate coverage on the stock with REDUCE and TP of Rs5,050/sh.

https://researchimgs.emkayglobal.com/emkay.png

Motorola Strengthens Leadership In India - Appoints- T.M. Narasimhan As Managing Director, Mobile Business Group - India

* T.M. Narasimhan will oversee the India business for Motorola 

Motorola Mobility India announced the appointment of Mr. T.M Narasimhan as the Managing Director,for Mobile Business Group - India.  

In line with its focus on the Indian smartphone market and the vision to be among the top 3 smartphone brands, Motorola has strengthened its India leadership team by appointing T.M. Narasimhan, to lead the India business; reporting to Mr. Prashanth Mani who will continue to be the head of Motorola’s Asia Pacific business.  

T.M. Narasimhan comes with extensive experience in sales operations, business & financial planning and P&L Management, having held various roles in FMCG, and consumer tech organizations like PepsiCo, Britannia & Samsung. With a proven track record of building & nurturing teams, he has consistently delivered business results while balancing short-term & long-term goals. 

Commenting on the new appointment Mr. Prashanth Mani, Executive Director - Motorola Asia Pacific, said, “As we continue our growth story in India, we are excited to welcome T.M. Narasimhan on board. India is a focus market for us in Asia pacific and has been seeing exponential growth over the past few years. We are confident that Narasimhan will play a pivotal role in leading the India team & elevating the business to even greater success.” 

Sharing his excitement, Mr. T.M Narasimhan, Managing Director, Mobile Business Group - India said: "I am excited to be a part of the Motorola family and look forward to contributing to the brand's growth journey in India. Motorola has been a pioneer in innovation and has been disrupting the smartphone market in India with its exceptional product strategy, innovative business model and brand prowess. I look forward to building upon the solid foundation that has been laid and taking the India business to new heights while consistently delivering on consumer experience and satisfaction.” 

Motorola in India has been consistently growing at a double-digit premium to market over the last year and has grown at 37% Premium to Market in Q2 FY23* despite a flat to declining market, which implies that the brand is acquiring market share rapidly. 

Leveraging the premiumization trend in the India, Motorola has disrupted the market with its razr 40 series and edge 40 series this year, growing the premium segment by over 2X^ YoY in H1 FY23-24. The Motorola razr 40 ultra and Motorola razr 40, designed to cater to modern consumers chasing a balanced smartphone experience have been the highest selling foldable proposition on Amazon during Prime Days’ 23~ and the Great Indian Festival'23~. Further, the Motorola edge 40 and edge 40 neo, the world’s slimmest and lightest IP68 rated phones, have disrupted the premium segment by bringing the perfect combination of flagship design, features and software experiences to Indian consumers.  

Staying true to its promise of democratizing technology, Motorola has also dominated the market with its popular moto g franchise that stands for providing premium features at more accessible price points, with extremely popular models like moto g54 5G and moto g84 5G in 2023. Motorola was also recognized as India’s best 5G smartphone brand of 2023** and has seen exponential growth YoY in its 5G smartphone activations.  

Further, Motorola is committed to the vision of Making in India and Making for the World, having successfully partnered with Dixon Technologies for manufacturing in India and was amongst the first participants of the PLI scheme by the Government of India, for mobile phones. Local manufacturing is not only enhancing Motorola’s ability to serve the Indian customers better, but also enabling exports from India to multiple other markets, including USA. 

Motorola’s strategic emphasis on innovation, design and colours through its exclusive partnership with Pantone, distinctive software experiences, uncompromised 5G and its commitment towards making products for India, in India uniquely positions the brand for accelerated growth.  

*Source: IDC Data 

Bank of Baroda Revises Its Interest Rates Upwards On Retail Term Deposits For Various Tenors By Upto 125 Basis Points

* With a greater focus on shorter term tenors, the higher interest rates will benefit depositors, while at the same time, protecting NIMs 

Bank of Baroda (Bank), one of India’s leading public sector banks announced an upward revision in the interest rates on Domestic Retail Term Deposits, including NRO Term Deposits, from 10 basis points to up to 125 basis points on various maturity buckets with effect from December 29, 2023. These rates are applicable on deposits below Rs 2 crore.  

The increase in rates are largely focused on shorter-term maturity buckets, specifically those less than 1 year. Increasing interest rates in shorter-term maturities will not only greatly benefit  depositors who keep deposits for shorter maturities but will also contribute to the Bank's objective of balancing and optimising the overall cost of deposits and protecting its Net Interest Margin (NIM). This is also in line with the Bank’s strategy to increase its share of shorter-term retail term deposits.   

Shri Ravindra Singh Negi, Chief General Manager - Retail Liabilities & NRI Business, Bank of Baroda said, “The decision to increase retail term deposit rates underscores Bank of Baroda's commitment to offering higher value to our customers, while strategically managing our deposit portfolio. We believe this step will not only attract more customers as they earn more on their savings, but will also help the Bank optimise its cost of deposits, thereby safeguarding our NIM.” 

Existing and new customers of Bank of Baroda can take advantage of the higher rates and open a FD through any of the Bank’s branches across India. An online FD can also be opened by existing customers via the Bank’s Mobile app (bob World)/ Net Banking (bob World Internet).